交易 CareDx Inc - CDNA 差價合約

當前暫時無法進行市場交易當前市場资讯 截至 2026-04-01 19:45:43
交易條件
類型
該金融市場可進行差價合約交易。
了解更多:差價合約
差價合約
點差0.12
長倉隔夜倉息調整
長倉隔夜倉息調整

保證金。您的投資
$1,000.00
隔夜倉息
來自頭寸全值的費用
-0.021651 %
(-$4.33)

使用杠杆的交易規模(大約值)$20,000.00

來自杠杆的資金 - 美元(大約值)$19,000.00


-0.02165%
短倉隔夜倉息調整
短倉隔夜倉息調整

保證金。您的投資
$1,000.00
隔夜倉息
來自頭寸全值的費用
-0.000571 %
(-$0.11)

使用杠杆的交易規模(大約值)$20,000.00

來自杠杆的資金 - 美元(大約值)$19,000.00


-0.00057%
隔夜倉息調整時間21:00 (UTC)
貨幣USD
最低成交量1
保證金5.00%
證券交易所United States of America
交易佣金10%
保證止損溢價
保證止損 (GSL) 費用僅在 GSL 被觸發時收取。更多詳情請參閱我們網站的「服務費用」 頁面。
1%

1我們執行交易收取的費用是點差,即買入價和賣出價之間的差額。有關更多資訊,請參閱我們網站上的收費頁面

主要統計數據
前收盤價17.32
開倉17.59
1 年變化-0.57%
日區間17.25 - 17.88

交易 CareDx Inc - CDNA 差價合約

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. It also has a collaborative research agreement with Eledon Pharmaceuticals, Inc. to use AlloSure for assessing the efficacy of Eledon''s investigational AT-1501 in the prevention of rejection in upcoming renal transplantation trials. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.

最新股票文章

一隻手正把硬幣放入另一人捧著、裝滿零錢的雙手中。
收息股:股息率分布、選股風險框架與高息ETF配置分析
2026年港股收息股與高息ETF的股息率結構、派息可持續性風險、估值環境及行業分散配置邏輯,涵蓋銀行股、REITs、公用事業及能源板塊的風險收益特徵分析
08:35, 27 3月 2026
平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026
阿里巴巴突破楔形整理
阿里巴巴突破楔形整理,AI 動能回溫帶動股價走勢
阿里巴巴(Alibaba)正逐漸成為 AI 領域中不可忽視的關鍵角色。
07:42, 14 1月 2026
特斯拉財報不及預期後的交易動向
特斯拉財報不及預期後的交易動向
第二季財報盈餘與營收皆未達預期,股價在盤後交易下跌,執行長馬斯克警告可能將面臨「幾個艱難的季度」
20:07, 24 7月 2025